Oxford Biomedica Solutions
Oxford Biomedica Solutions, a leading player in the biopharmaceutical industry, is headquartered in the United States, with significant operational regions across North America and Europe. Founded in 1995, the company has established itself as a pioneer in gene and cell therapy, providing innovative solutions that enhance the development and manufacturing of advanced therapeutics. Specialising in viral vector manufacturing, Oxford Biomedica Solutions offers a unique platform that supports the production of high-quality vectors for gene therapies and vaccines. Their commitment to excellence has positioned them as a trusted partner for biotech and pharmaceutical companies globally. With a strong track record of successful collaborations and notable achievements, Oxford Biomedica Solutions continues to drive advancements in the life sciences sector, making a significant impact on patient outcomes.
DitchCarbon Score
How does Oxford Biomedica Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Oxford Biomedica Solutions's score of 3 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Oxford Biomedica Solutions's reported carbon emissions
Oxford Biomedica Solutions, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting its emissions. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and reducing their carbon footprints. While specific initiatives or targets from Oxford Biomedica Solutions are not detailed, the industry trend indicates a growing emphasis on transparency and accountability regarding carbon emissions. As the company progresses, it may adopt industry-standard practices for measuring and reporting emissions across Scope 1, 2, and 3 categories, which encompass direct emissions, indirect emissions from energy consumption, and other indirect emissions throughout the value chain.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Oxford Biomedica Solutions is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
